Bioenergetic age, or how efficiently cells produce energy, could predict Alzheimer’s risk, with healthy lifestyle choices ...

Scientists have discovered that how well a person’s cells generate energy—what they call “bioenergetic age”—could be a strong ...

Researchers have discovered that a person's "bioenergetic age," reflecting how efficiently cells produce energy, strongly ...

Spatial transcriptomics on human brains parsed microglial reactions to amyloid immunotherapy. Both a vaccine and a therapeutic antibody summoned these cells to plaques. Responders expressed TREM2, ...

A person's "bioenergetic age"—or how youthfully their cells generate energy—might be a key indicator of whether they're at ...

Chicago area scientists have identified the genes that drive the process of Alzheimer’s disease and are working to make the drug Lecanemab even better by identifying which genes are active ...

While researchers continue to work on a full cure for Alzheimer's disease, they're finding treatments that can help manage ...

Lecanemab, marketed as Leqembi, is one such antibody that has gained attention. Developed by Eisai and Biogen, it received accelerated approval from the U.S. Food and Drug Administration in January ...

Why are researchers still fumbling in the quest to cure what is arguably one of the most important diseases confronting ...

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...